First Republic Investment Management Inc. lowered its stake in shares of Humana Inc (NYSE:HUM) by 23.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,798 shares of the insurance provider’s stock after selling 554 shares during the quarter. First Republic Investment Management Inc.’s holdings in Humana were worth $477,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. LS Investment Advisors LLC lifted its position in Humana by 1.8% during the second quarter. LS Investment Advisors LLC now owns 4,512 shares of the insurance provider’s stock valued at $1,197,000 after purchasing an additional 78 shares during the period. Commerce Bank increased its stake in shares of Humana by 5.4% in the second quarter. Commerce Bank now owns 4,957 shares of the insurance provider’s stock worth $1,315,000 after purchasing an additional 254 shares in the last quarter. Sound View Wealth Advisors Group LLC purchased a new stake in shares of Humana in the second quarter worth $313,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in Humana by 263.2% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,496 shares of the insurance provider’s stock valued at $7,825,000 after acquiring an additional 21,375 shares in the last quarter. Finally, Calamos Wealth Management LLC grew its stake in Humana by 289.8% during the second quarter. Calamos Wealth Management LLC now owns 16,077 shares of the insurance provider’s stock valued at $4,265,000 after acquiring an additional 11,953 shares in the last quarter. Institutional investors own 92.90% of the company’s stock.
In related news, insider Brian P. Leclaire sold 7,239 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the completion of the sale, the insider now directly owns 12,994 shares of the company’s stock, valued at $3,764,361.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.54% of the stock is owned by company insiders.
Shares of HUM traded up $6.31 during mid-day trading on Friday, hitting $274.69. 939,733 shares of the company’s stock were exchanged, compared to its average volume of 876,997. The stock’s 50-day moving average is $287.14 and its 200-day moving average is $269.38. The company has a market cap of $37.40 billion, a price-to-earnings ratio of 18.88, a P/E/G ratio of 1.20 and a beta of 0.84. Humana Inc has a fifty-two week low of $225.65 and a fifty-two week high of $355.88. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.75 and a current ratio of 1.75.
Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $5.24 by $0.81. The firm had revenue of $16.25 billion for the quarter, compared to analysts’ expectations of $15.88 billion. Humana had a net margin of 4.13% and a return on equity of 22.47%. The firm’s revenue was up 13.9% compared to the same quarter last year. During the same quarter last year, the company earned $3.96 earnings per share. As a group, equities research analysts anticipate that Humana Inc will post 17.63 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.80%. The ex-dividend date is Friday, September 27th. Humana’s dividend payout ratio is presently 15.12%.
Several equities analysts have commented on the stock. Piper Jaffray Companies increased their price objective on shares of Humana from $315.00 to $341.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. Cantor Fitzgerald upgraded shares of Humana from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $300.00 to $345.00 in a research report on Monday, August 12th. UBS Group raised their target price on shares of Humana from $266.00 to $317.00 and gave the stock a “neutral” rating in a report on Thursday, August 1st. SunTrust Banks raised their target price on shares of Humana to $340.00 and gave the company a “hold” rating in a research report on Thursday, August 1st. Finally, Deutsche Bank assumed coverage on shares of Humana in a research report on Thursday. They set a “hold” rating on the stock. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have issued a buy rating to the stock. Humana has an average rating of “Buy” and a consensus price target of $341.95.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also: What causes a yield curve to invert?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.